A simian immunodeficiency virus macaque model of highly active antiretroviral treatment: Viral latency in the periphery and the central nervous system

Current Opinion in HIV and AIDS

Volumn 6, Issue 1, 2011, Pages 37-42

  Clements, Janice E ^a   Gama, Lucio ^a   Graham, David R ^a,b   Mankowski, Joseph L ^a   Zink, M C ^a,c  

^a Department of Molecular and Comparative Pathobiology ^*  (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Central nervous system; Highly active antiretroviral treatment; Macaque; Reservoirs; Simian immunodeficiency virus

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; INTEGRASE INHIBITOR; L 870812; SAQUINAVIR; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS RNA;

ARTICLE; CD4+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID ANALYSIS; ERADICATION THERAPY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNE RESPONSE; MACACA; NEUROLOGIC DISEASE; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS GENOME; VIRUS INFECTION; VIRUS LATENCY; VIRUS LOAD; VIRUS REPLICATION; ANIMAL; BONE MARROW; DISEASE MODEL; HEMATOPOIETIC STEM CELL; PATHOGENICITY; REVIEW; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VIROLOGY;

ANIMALS; BONE MARROW; CENTRAL NERVOUS SYSTEM; DISEASE MODELS, ANIMAL; HEMATOPOIETIC STEM CELLS; HUMANS; MACACA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS LATENCY;

EID: 79954449242     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3283412413     Document Type: Article

References (29)

1. Kader M, Hassan WM, Eberly M, et al. Antiretroviral therapy prior to acute viral replication preserves CD4 T cells in the periphery but not in rectal mucosa during acute simian immunodeficiency virus infection. J Virol 2008; 82:11467-11471.
2. Verhoeven D, Sankaran S, Silvey M, et al. Antiviral therapy during primary simian immunodeficiency virus infection fails to prevent acute loss of CD4+ T cells in gut mucosa but enhances their rapid restoration through central memory T cells. J Virol 2008; 82:4016-4027. (Pubitemid 351521237)
3. Dinoso JB, Rabi SA, Blankson JN, et al. A simian immunodeficiency virusinfected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. J Virol 2009; 83:9247-9257.
4. Sellier P, Mannioui A, Bourry O, et al. Antiretroviral treatment start-time during primary SIV(mac) infection in macaques exerts a different impact on early viral replication and dissemination. PLoS One 2010; 5:e10570.
5. Sellier P, Mannioui A, Bourry O, et al. Antiretroviral treatment start-time during primary SIV(mac) infection in macaques exerts a different impact on early viral replication and dissemination. PLoS One 2010; 5:e10570.
6. Annamalai L, Bhaskar V, Pauley DR, et al. Impact of short-term combined antiretroviral therapy on brain virus burden in simian immunodeficiency virusinfected and CD8+ lymphocyte-depleted rhesus macaques. Am J Pathol 2010; 177:777-791.
7. Babas T, Dewitt JB, Mankowski JL, et al. Progressive selection for neurovirulent genotypes in the brain of SIV-infected macaques. AIDS 2006; 20:197-205.
8. Witwer KW, Gama L, Li M, et al. Coordinated regulation of SIV replication and immune responses in the CNS. PLoS One 2009; 4:e8129.
9. Zink MC, Clements JE. A novel simian immunodeficiency virus model that provides insight into mechanisms of human immunodeficiency virus central nervous system disease. J Neurovirol 2002; 8:42-48. (Pubitemid 36097775)
10. Zink MC, Suryanarayana K, Mankowski JL, et al. High viral load in the cerebrospinal fluid and brain correlates with severity of simian immunodeficiency virus encephalitis. J Virol 1999; 73:10480-10488.
11. Overholser ED, Coleman GD, Bennett JL, et al. Expression of simian immunodeficiency virus (SIV) nef in astrocytes during acute and terminal infection and requirement of nef for optimal replication of neurovirulent SIV in vitro. J Virol 2003; 77:6855-6866. (Pubitemid 36666879)
12. Mankowski JL, Queen SE, Clements JE, et al. Cerebrospinal fluid markers that predict SIV CNS disease. J Neuroimmunol 2004; 157:66-70. (Pubitemid 39576639)
13. Clements JE, Babas T, Mankowski JL, et al. The central nervous system as a reservoir for simian immunodeficiency virus (SIV): steady-state levels of SIV DNA in brain from acute through asymptomatic infection. J Infect Dis 2002; 186:905-913.
14. Barber SA, Gama L, Dudaronek JM, et al. Mechanism for the establishment of transcriptional HIV latency in the brain in a simian immunodeficiency virusmacaque model. J Infect Dis 2006; 193:963-970.
15. Barber SA, Herbst DS, Bullock BT, et al. Innate immune responses and control of acute simian immunodeficiency virus replication in the central nervous system. J Neurovirol 2004; 10:15-20. (Pubitemid 38325088)
16. Zink MC, Brice A, Kelly K, et al. SIV-infected macaques treated with highly active antiretroviral therapy (HAART) have reduced CNS virus replication and inflammation but persistence of viral DNA. J Infect Dis 2010; 202:161-170.
17. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1- infected compartments during combination therapy. Nature 1997; 387:188-191. (Pubitemid 27209434)
18. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337:725-733. (Pubitemid 27417971)
19. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337:734-739. (Pubitemid 27417972)
20. Shen A, Zink MC, Mankowski JL, et al. Resting CD4+ T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-Macaca nemestrina model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy. J Virol 2003; 77:4938-4949. (Pubitemid 36402842)
21. + T cells in the simian immunodeficiency virus/macaque model of human immunodeficiency virus type 1 latency. J Virol 2007; 81: 1660-1670. (Pubitemid 46214441)
22. Blankson JN, Finzi D, Pierson TC, et al. Biphasic decay of latently infected CD4+ T cells in acute human immunodeficiency virus type 1 infection. J Infect Dis 2000; 182:1636-1642.
23. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387:183-188. (Pubitemid 27209433)
24. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65:65-70.
25. Zink MC, Coleman GD, Mankowski JL, et al. Increased macrophage chemoattractant protein-1 in cerebrospinal fluid precedes and predicts simian immunodeficiency virus encephalitis. J Infect Dis 2001; 184:1015-1021. (Pubitemid 32955118)
26. Sacktor N, Lyles RH, Skolasky R, et al. HIV-associated neurologic disease incidence changes. Multicenter AIDS Cohort Study, 1990-1998. Neurology 2001; 56:257-260. (Pubitemid 32095372)
27. Tozzi V, Balestra P, Galgani S, et al. Changes in neurocognitive performance in a cohort of patients treated with HAART for 3 years. J Acquir Immune Defic Syndr 2001; 28:19-27. (Pubitemid 33104523)
28. Fox HS, Weed MR, Huitron-Resendiz S, et al. Antiviral treatment normalizes neurophysiological but not movement abnormalities in simian immunodeficiency virus-infected monkeys. J Clin Invest 2000; 106:37-45. (Pubitemid 30437238)
29. Marcondes MC, Flynn C, Huitron-Rezendiz S, et al. Early antiretroviral treatment prevents the development of central nervous system abnormalities in simian immunodeficiency virus-infected rhesus monkeys. AIDS 2009; 23:1187-1195.